Viromed Medical Charts a New Course With Acquisition, OEM Launch, and Regulatory Push

Viromed Medical pivots to a vertically integrated tech firm via plasma acquisition, OEM production for Hellmut Ruck, and MDR approval for ViroCAP med, boosting shares 37%.

Viromed Medical is executing on multiple fronts simultaneously as it reshapes itself from a distribution-focused operation into a vertically integrated technology company. The strategy hinges on three pillars: the planned acquisition of a plasma technology specialist, the start of original equipment manufacturing for a key partner, and progress toward regulatory approval for its own medical devices.

Acquisition to Bring In-House Capabilities

The centerpiece of the transformation is the proposed purchase of relyon plasma GmbH, a TDK Electronics subsidiary based in Regensburg. Viromed signed a letter of intent in March 2026 to acquire all shares of the company, with the price expected to fall in the low-to-mid double-digit million euro range. The deal remains subject to a successful due diligence process, with management targeting completion in the second quarter of 2026.

Bringing relyon plasma in-house would give Viromed its own research and manufacturing capacity for atmospheric cold plasma technology, along with an international patent portfolio. The move is designed to sharply reduce the company’s reliance on external production partners.

OEM Production Underway

While the acquisition process moves forward, Viromed has already begun commercial production. Late April saw the start of series manufacturing for an OEM version of its ViroCAP® cold plasma medical device, developed for podology specialist Hellmut Ruck GmbH. Ruck will distribute the device exclusively in the podology sector across Europe, the United Kingdom, and Switzerland, tapping into a customer network of more than 120,000 contacts.

International expansion is also taking shape. Viromed is working on a distribution agreement that would cover the United Arab Emirates, Qatar, Saudi Arabia, and Kuwait, for both human and veterinary applications.

Regulatory Hurdles Remain

The company’s longer-term ambitions depend on clearing regulatory milestones. ViroCAP med, a system for chronic wound healing, is currently going through the MDR Class IIa approval process. Management does not expect a full human medical rollout until 2026. The targeted double-digit operating profit margin is directly tied to this timeline.

Another project, the PulmoPlas® system, aims to integrate cold plasma into ventilator processes to combat ventilator-associated pneumonia — an approach for which no comparable systems currently exist. The German Federal Ministry for Research, Technology and Space has awarded Viromed a high six-figure grant to support this development. Partners include Hannover Medical School and the Helmholtz Centre for Infection Research. A 35 percent stake in a spin-off from Saarland University secures the research model underpinning the project.

Market Response and Key Dates Ahead

Investors have taken note of the strategic moves. Viromed’s shares have climbed roughly 37 percent over the past 30 days, reaching €7.25 on Thursday. That puts the company’s market capitalization at around €144 million. The stock now trades well above its 50-day moving average of €5.92, though it remains about eight percent below its 52-week high. The annualized volatility stands at nearly 72 percent.

The next major test arrives in May, when Viromed publishes its annual financial statements — the first hard numbers that will shed light on the financial foundation underpinning the expansion strategy. The annual general meeting follows in July 2026, where shareholders will expect concrete details on the future capital structure and how management plans to fund the ambitious overhaul.